Premium
Plasma cytokines eotaxin, MIP‐1α, MCP‐4, and vascular endothelial growth factor in acute lower respiratory tract infection
Author(s) -
Relster Mette Marie,
Holm Anette,
Pedersen Court
Publication year - 2017
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12636
Subject(s) - eotaxin , medicine , lower respiratory tract infection , macrophage inflammatory protein , respiratory tract , immunology , respiratory tract infections , pathogenesis , cytokine , proinflammatory cytokine , vascular endothelial growth factor , c reactive protein , respiratory system , gastroenterology , chemokine , inflammation , interleukin , vegf receptors
Major overlaps of clinical characteristics and the limitations of conventional diagnostic tests render the initial diagnosis and clinical management of pulmonary disorders difficult. In this pilot study, we analyzed the predictive value of eotaxin, macrophage inflammatory protein 1 alpha ( MIP ‐1α), monocyte chemoattractant protein 4 ( MCP ‐4), and vascular endothelial growth factor ( VEGF ) in 40 patients hospitalized with acute lower respiratory tract infections ( LRTI ). The cytokines contribute to the pathogenesis of several inflammatory respiratory diseases, indicating a potential as markers for LRTI . Patients were stratified according to etiology and severity of LRTI , based on baseline C‐reactive protein and CURB ‐65 scores. Using a multiplex immunoassay of plasma, levels of eotaxin and MCP ‐4 were shown to increase from baseline until day 6 after admission to hospital. The four cytokines were unable to predict the etiology and severity. Eotaxin and MCP ‐4 were significantly lower in patients with C‐reactive protein ≥100, and MIP ‐1α was significantly higher in the patients with CURB ‐65 > 3, but the predictive power was low. In conclusion, further evaluation, including more patients, is required to assess the full potential of eotaxin, MCP ‐4, MIP ‐1α, and VEGF as biomarkers for LRTI because of their low predictive power and a high interindividual variation of cytokine levels.